Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430973 · ClinicalTrials.gov registry record · NA
Aggressive Driving and Road Rage: A Driving Simulation Experiment.
A NA study, sponsored by Ohio State University.
- Terminated
- Registry status
- NA
- Development phase
- 85
- Enrollment target
NCT03430973: Clinical Trial NA study, sponsored by Ohio State University.
NCT03430973 is a NA study that was terminated before completion, run by Ohio State University. The registered enrollment target is 85 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03430973, a NA study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
Study Summary
Driving a car is the most dangerous behavior most people engage in every day. According to the World Health Organization, about 1.25 million people die each year as a result of road traffic crashes, and they are the leading cause of death among 15 to 29 year olds. According to the National Highway Traffic Safety Administration, 37,461 Americans were killed in motor vehicle crashes in 2016 - about 103 per day. Although there are several causes of traffic crashes (e.g., texting, alcohol consumption, inclement weather), the leading cause is aggressive driving. In the United States, aggressive driving accounts for more than half of all traffic fatalities. Thus, aggressive driving is an important applied health topic, especially for young drivers.
Primary Outcome
The two primary measures of aggressive driving will be tailgating and speeding. Tailgating measures are based on the number of seconds between the participant's car and the car in front of them: (1) 4-second rule (recommended for speeds above 30 MPH, in heavy traffic, or when there are many obstacles, as in the present driving scenario), (2) 3-second rule (dangerous), and (3) 2-second rule (extremely dangerous). Average speed is a poor measure of speeding because it depends heavily on random inf
Interventions
- BEHAVIORAL Music
- BEHAVIORAL Videos
- BEHAVIORAL Alcohol-related cues
- BEHAVIORAL Bumper stickers
- BEHAVIORAL Roadside vegetation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2015-10-20 |
| Est. Completion | 2025-12-01 |
| Phase | NA |
Why NCT03430973 stopped before completion
NCT03430973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Music is the first listed.
NCT03430973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03430973 about?
NCT03430973 is a clinical study titled "Aggressive Driving and Road Rage: A Driving Simulation Experiment.". Driving a car is the most dangerous behavior most people engage in every day. According to the World Health Organization, about 1.25 million people die each year as a result of road traffic crashes, and they are the leading cause of death among 15 to 29 year olds. According to the National Highway T...
What is the current status of trial NCT03430973?
This trial is currently terminated. It is a NA study. The enrollment target is 85 participants. The study started on 2015-10-20. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT03430973?
The interventions under investigation include: Music (BEHAVIORAL), Videos (BEHAVIORAL), Alcohol-related cues (BEHAVIORAL), Bumper stickers (BEHAVIORAL), Roadside vegetation (BEHAVIORAL).
Who is sponsoring clinical trial NCT03430973?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03430973's enrollment target sits among peer trials
85 980th of 2000 higher than 1,018 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI